- Home
- PLSE vs RCUS Comparison
PLSE vs RCUS Comparison
Compare PLSE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | RCUS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.2B |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PLSE | RCUS |
|---|---|---|
| Price | $52.82 | $24.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $56.50 | $39.91 |
| AVG Volume (30 Days) | 483.5K | ★ 1.5M |
| Earning Date | 11-04-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | $477.71 | N/A |
| Revenue Next Year | $233.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.56 | $15.09 |
| 52 Week High | $58.90 | $31.74 |
Technical Indicators
Market Signals| Indicator | PLSE | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 57.23 | 40.10 |
| Support Level | $49.01 | $23.91 |
| Resistance Level | $57.82 | $26.43 |
| Average True Range (ATR) | 2.79 | 1.15 |
| MACD | -0.36 | -0.01 |
| Stochastic Oscillator | 58.11 | 30.59 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.